DJ Affluent Medical: Increase in resources allocated to the liquidity contract with Kepler Cheuvreux.
Affluent Medical
Affluent Medical: Increase in resources allocated to the liquidity contract with Kepler Cheuvreux.
10-Jul-2023 / 17:45 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
PRESS RELEASE
Increase in resources allocated to the liquidity contract
with Kepler Cheuvreux
Aix-en-Provence, July 10, 2023 - 5:30 pm CET- Affluent Medical (ISIN code: FR0013333077 - ticker: AFME), a French
MedTech specializing in the international development and industrialization of innovative medical prostheses, at a
clinical stage, to treat mitral heart valve pathology and urinary incontinence, today announced an increase in the
resources allocated to the liquidity contract entered into with Kepler Cheuvreux, with the aim of improving the
liquidity of the share.
In accordance with the provisions of Article 4 of AMF Decision no. 2021-01 of June 22, 2021 (the "AMF Decision"),
Affluent Medical today increased the resources allocated to the liquidity contract with Kepler Cheuvreux by 35,000
euros.
Following this increase in the cash amount allocated to the liquidity contract, the available resources are as follows:
- 124 232 shares
- 39,957.10 EUR
About Affluent Medical
Affluent Medical is a French MedTech company, founded by Truffle Capital, with the ambition to become a global leader
in the treatment of structural heart diseases, which are the world's leading cause of mortality, and urinary
incontinence which currently affects one in four adults.
Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore
critical physiological functions. The product candidates developed by the Company are currently in preclinical and
clinical studies.
KaliosTM, the first mitral adjustable annuloplasty ring, should be the first Affluent Medical device to be marketed.
Subject to raising the necessary funds to finance its strategy and to positive results from ongoing clinical studies,
the Company's ambition is to progressively commercialize its products starting in 2025.
For more information: www.affluentmedical.com
Contacts:
AFFLUENT MEDICAL ACTIFIN, financial communications
Sébastien Ladet Ghislaine Gasparetto
Chief Executive Officer +33 (0)6 21 10 49 24
investor@affluentmedical.com affluentmedical@actifin.fr
ACTIFIN, financial press relations
PRIMATICE, public relations France
Jennifer Jullia Thomas Roborel de Climens
+33 (0)6 78 12 97 95
+33 (0)1 56 88 11 19
thomasdeclimens@primatice.com
jjullia@actifin.fr
-----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file File: Affluent Medical - Liquidity contract EN
=-------------------------------------------------------------------------------------------------------
Language: English
Company: Affluent Medical
320 avenue Archimède, Les pléiades III Bâtiment B
13100 Aix en Provence France
France
Phone: +33 4 42 95 12 20
E-mail: jerome.geoffroy@affluentmedical.com
Internet: https://www.affluentmedical.com/
ISIN: FR0013333077
Euronext Ticker: AFME
AMF Category: Share buyback / Disposal of own shares / Information relating to the liquidity contract
EQS News ID: 1676587
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1676587 10-Jul-2023 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1676587&application_name=news
(END) Dow Jones Newswires
July 10, 2023 11:45 ET (15:45 GMT)
